Raymond James analyst Steven Seedhouse maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report) today and set a price target of $75.00. The company's shares closed last Thursday at $25.03. According to TipRanks.com, Seedhouse is a 2-star analyst with an average return of 0.4% and a 39.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, NGM Biopharmaceuticals, and Galmed Pharmaceuticals. Mirum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $57.80, implying a 141.8% upside from current levels.
https://www.tipranks.com/news/blurbs/mirum-pharmaceuticals-mirm-receives-a-buy-from-raymond-james?utm_source=advfn.com&utm_medium=referral
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Mirum Pharmaceuticals Charts.
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Mirum Pharmaceuticals Charts.